QurCan Therapeutics has announced a strategic research and collaboration agreement with Lilly to advance nucleic acid therapies for diseases affecting the central and peripheral nervous systems. The collaboration will focus on developing genetic medicine therapeutics using QurCan’s proprietary TERP™ (Target-Engineered Responsive Polymer) platform, a non-viral delivery technology designed to help deliver genetic medicines to disease-relevant cells.
Under the agreement, QurCan will lead the optimization of therapeutic candidates using its delivery platform, while Lilly will oversee further research, clinical development, and commercialization of selected programs. The partnership highlights growing interest in next-generation approaches to treating neurological diseases, an area where effective delivery of genetic medicines remains a significant challenge.
The collaboration also includes an upfront payment and strategic investment from Lilly, with the potential for additional research, development, and commercial milestone payments. For QurCan, the agreement represents an important validation of its technology and its potential to support the development of new therapies for neurological conditions.
Read more about the collaboration and its potential impact on neurological disease treatment.
